Flputnam Investment Management Co. Purchases 397 Shares of Amgen Inc. (NASDAQ:AMGN)

Flputnam Investment Management Co. grew its position in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 53,704 shares of the medical research company’s stock after acquiring an additional 397 shares during the quarter. Flputnam Investment Management Co.’s holdings in Amgen were worth $15,468,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after buying an additional 165,636 shares during the last quarter. Morgan Stanley increased its holdings in shares of Amgen by 12.9% during the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Amgen by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after purchasing an additional 94,565 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after purchasing an additional 7,532,031 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of Amgen stock traded down $1.77 during trading hours on Monday, hitting $265.51. 1,731,820 shares of the company were exchanged, compared to its average volume of 2,883,530. The business has a 50-day moving average of $280.76 and a 200-day moving average of $281.55. The stock has a market capitalization of $142.29 billion, a price-to-earnings ratio of 21.40, a P/E/G ratio of 2.53 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.09 earnings per share. As a group, analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AMGN shares. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and boosted their price target for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Finally, Oppenheimer restated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.